Lexaria Bioscience
Kelowna, British Columbia, Canada · Biotechnology, Healthcare, Other
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on improving the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. The company has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats, and operates a licensed in-house research laboratory. Additionally, the company holds
Key facts
- Headquarters
- Kelowna, British Columbia, Canada
- Employees
- 10
- Industries
- Biotechnology, Healthcare, Other
- Status
- Public (LEXX)
- Website
- www.lexariabioscience.com
- Company page
Recent activity at Lexaria Bioscience
- : Lexaria Bioscience
- : SEC 8-K (1.01): On September 7, 2026, Lexaria Bioscience Corp. entered into inducement offer letter agreements with certain holders of existing common stock purchase warrants. These agreements pertain to the early exercise of warrants originally issued on four different dates between February 16, 2024, and December 16, 2025, with varying exercise prices. The total number of shares subject to these agreements is 453,969, which could significantly impact the company's equity structure and capital availability. This move reflects a strategy to encourage warrant holders to exercise their rights earlier than expected, potentially raising capital for the company.
- : SEC 8-K (8.01): On August 28, 2026, Lexaria Bioscience Corp.'s wholly-owned subsidiary, Lexaria (AU) Pty Ltd, received an Australian R&D Tax Incentive Credit amounting to AUD$3,666,611.98 (approximately USD$2.6 million) from the Australian Tax Office. This credit is in relation to research and development expenses incurred for the clinical study GLP-1-H24-4. The funds have been deposited in Lexaria (AU) Pty Ltd's Australian bank account and are earmarked for future research and development initiatives in Australia. This financial incentive represents significant support for Lexaria's ongoing projects involving DehydraTECH technology with pharmaceutical products in the Australian market.
- : SEC 8-K (8.01): On August 17, 2026, Lexaria Bioscience Corp. received confirmation from the Nasdaq Listings Qualifications Staff that it has regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2). This followed a prior indication that the company was at risk of delisting due to its stock price falling below the required threshold. As a result, the previously requested hearing has been cancelled, allowing the company's Common Stock to continue listing and trading on The Nasdaq Capital Market. This is a significant development as it ensures the company maintains its public market standing.
- : Lexaria Bioscience
- : SEC 8-K (1.01): On December 14, 2025, Lexaria Bioscience Corp. entered into a securities purchase agreement with institutional investors, where it issued and sold 2,661,600 shares of Common Stock at a price of $1.315 per share and concurrently offered 2,661,600 common stock purchase warrants exercisable for up to 2,661,600 shares of Common Stock at an exercise price of $1.19. This transaction was conducted under the Company’s shelf registration statement and included customary representations, warranties, and agreements. The Private Placement Warrants are exercisable upon issuance and will expire on the fifth anniversary of the effective date of the registration statement but may also be exercised on a cashless basis. Failure to deliver shares promptly upon valid exercise incurs liquidated damages to the warrant holders.
- : SEC 8-K (1.01): On December 14, 2025, Lexaria Bioscience Corp. entered into a securities purchase agreement with institutional investors. The Company issued 2,661,600 shares of its Common Stock at a price of $1.315 per share in a registered direct offering and concurrently sold 2,661,600 common stock purchase warrants, which are exercisable for an aggregate of up to 2,661,600 shares of Common Stock at an exercise price of $1.19 per share. This transaction signifies a strategic move to raise capital through the equity markets, providing the Company with additional funds for expansion or operational expenses.
- : Lexaria Bioscience
- : Lexaria Bioscience
- : Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer
Lexaria Bioscience funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Venture | $113K |
| Dec 2025 | Venture | $3.5M |
| Oct 2025 | Seed | $4.0M |
| Oct 2024 | Venture | $5.0M |
| May 2024 | Seed | $365K |
Leadership
- CHRISTOPHER BUNKA, Executive Officer, Director
- JOHN DOCHERTY, Executive Officer, Director
- NICHOLAS BAXTER, Director
- TED MCKECHNIE, Director
- ALBERT REESE, Director
- CHRIS BUNKA, Executive Officer, Director
Verified email and direct lines for Lexaria Bioscience’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Lexaria Bioscience in the news
- Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance (Sep 04, 2026)
- Lexaria Announces Results from Animal Study GLP-1-A26-1 - Investing News Network (Oct 15, 2026)
- Lexaria Biosciences and Cannadips CBD reached definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category - Investing News Network (Jan 14, 2020)
- Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category - Investing News Network (Jan 22, 2020)
Companies similar to Lexaria Bioscience
- TriFlo Cardiovascular Inc · Biotechnology, Healthcare, Other
- Vigil Neuroscience · Biotechnology, Healthcare, Other
- Aclarion · Biotechnology, Healthcare, Other
- LUMINOPIA · Biotechnology, Healthcare, Other
- Kalera Medical, Inc. · Biotechnology, Healthcare, Other
About Lexaria Bioscience: questions and answers
What does Lexaria Bioscience do?
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on improving the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. The company has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats, and operates a licensed in-house research laboratory. Additionally, the company holds
Where is Lexaria Bioscience headquartered?
Lexaria Bioscience is headquartered in Kelowna, British Columbia, Canada.
How many employees does Lexaria Bioscience have?
Lexaria Bioscience has about 10 employees.
Has Lexaria Bioscience raised funding?
Yes. Fundz has recorded 5 funding events for Lexaria Bioscience. The most recent, $113K, was in Sep 2026.
What is the latest news on Lexaria Bioscience?
On Sep 21, 2026, Lexaria Bioscience
Is Lexaria Bioscience a public company?
Yes. Lexaria Bioscience is publicly traded under the ticker LEXX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy